Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference
- PMID: 36008461
- PMCID: PMC9406262
- DOI: 10.1038/s41598-022-18507-y
Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference
Abstract
To date, more than 263 million people have been infected with SARS-CoV-2 during the COVID-19 pandemic. In many countries, the global spread occurred in multiple pandemic waves characterized by the emergence of new SARS-CoV-2 variants. Here we report a sequence and structural-bioinformatics analysis to estimate the effects of amino acid substitutions on the affinity of the SARS-CoV-2 spike receptor binding domain (RBD) to the human receptor hACE2. This is done through qualitative electrostatics and hydrophobicity analysis as well as molecular dynamics simulations used to develop a high-precision empirical scoring function (ESF) closely related to the linear interaction energy method and calibrated on a large set of experimental binding energies. For the latest variant of concern (VOC), B.1.1.529 Omicron, our Halo difference point cloud studies reveal the largest impact on the RBD binding interface compared to all other VOC. Moreover, according to our ESF model, Omicron achieves a much higher ACE2 binding affinity than the wild type and, in particular, the highest among all VOCs except Alpha and thus requires special attention and monitoring.
© 2022. The Author(s).
Conflict of interest statement
V.D., K.K., A.S., An.K., D.N., Al.K., L.P., C.K., V.R., U.K. report working for Innophore. L.C., M.K., R.B., report working for Amazon Web Services, a company that also provides cloud computing services. K.G., G.S., C.C.G. report being shareholders of Innophore, an enzyme and drug discovery company. Additionally, G.S. and C.C.G. report being managing directors of Innophore. The research described here is scientifically and financially independent of the efforts in any of the above mentioned companies and open-science.
Figures



Similar articles
-
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19).2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34033342 Free Books & Documents.
-
Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.Chem Biol Interact. 2022 Dec 1;368:110244. doi: 10.1016/j.cbi.2022.110244. Epub 2022 Nov 3. Chem Biol Interact. 2022. PMID: 36336003 Free PMC article.
-
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.J Virol. 2021 Jul 26;95(16):e0061721. doi: 10.1128/JVI.00617-21. Epub 2021 Jul 26. J Virol. 2021. PMID: 34105996 Free PMC article.
-
Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.J Med Virol. 2022 Oct;94(10):4780-4791. doi: 10.1002/jmv.27927. Epub 2022 Jun 16. J Med Virol. 2022. PMID: 35680610 Free PMC article.
-
Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).Mini Rev Med Chem. 2021;21(6):689-703. doi: 10.2174/1389557520666201117111259. Mini Rev Med Chem. 2021. PMID: 33208074 Review.
Cited by
-
SARS-CoV-2 detection by targeting four loci of viral genome using graphene oxide and gold nanoparticle DNA biosensor.Sci Rep. 2022 Nov 12;12(1):19416. doi: 10.1038/s41598-022-23996-y. Sci Rep. 2022. PMID: 36371566 Free PMC article.
-
Structural Profiles of SARS-CoV-2 Variants in India.Curr Microbiol. 2022 Nov 22;80(1):1. doi: 10.1007/s00284-022-03094-y. Curr Microbiol. 2022. PMID: 36414797 Free PMC article.
-
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiX.Sci Rep. 2023 Jul 21;13(1):11783. doi: 10.1038/s41598-023-39071-z. Sci Rep. 2023. PMID: 37479788 Free PMC article.
-
Cavity-Based Discovery of New Fatty Acid Photodecarboxylases.Chembiochem. 2024 Dec 16;25(24):e202400631. doi: 10.1002/cbic.202400631. Epub 2024 Nov 9. Chembiochem. 2024. PMID: 39314172 Free PMC article.
-
CavitOmiX Drug Discovery: Engineering Antivirals with Enhanced Spectrum and Reduced Side Effects for Arboviral Diseases.Viruses. 2024 Jul 24;16(8):1186. doi: 10.3390/v16081186. Viruses. 2024. PMID: 39205160 Free PMC article.
References
-
- WHO. Coronavirus disease (COVID-19) pandemic, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2021).
Publication types
MeSH terms
Substances
Supplementary concepts
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous